4 completed. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow NDV-HXP-S COVID-19 vaccine: new trials by email Literature Review of NDV-HXP-S COVID-19 vaccine trials Research Report on NDV-HXP-S COVID-19 vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine NDV-HXP-S 10μg, BNT162b2 30μg - Coronavirus Infections, Healthy | Phase 2 / Phase 3 | Completed | Butantan Institute | 4400 | 2023-02-28 | 2025-02-06 |
| A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose - SARS-CoV-2 | Phase 1 | Completed | Sean Liu | 35 | 2022-02-09 | 2025-04-17 |
| Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil NDV-HXP-S 1μg, NDV-HXP-S 3μg, NDV-HXP-S 10μg - Coronavirus Infections, Healthy | Phase 1 | Completed | Butantan Institute | 320 | 2021-07-09 | 2023-08-21 |
| Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Normal Saline, NDV-HXP-S vaccine - Covid-19, SARS Pneumonia | Phase 1 / Phase 2 | Completed | Mahidol University | 455 | 2021-03-20 | 2022-11-15 |
COVID-19 (4) · Coronavirus Infections (2) · Pneumonia, Viral (1)
Butantan Institute (2) · Mahidol University (1) · Sean Liu (1)
Brazil (2) · Thailand (1) · United States (1)
Fernanda Castro Boulos, MD,PhD (1) · Punnee Pitisutthithum (1) · Sean Liu, MD, PhD (1)
PMID 34580673, PMID 35284808, PMID 36435633, PMID 39667115, PMID 40037239, PMID 42378814